



IQ Biozoom

NON-INVASIVE HOME DIAGNOSTICS



**What diabetics, people with
hormonal disorders and
athletes have in common?**



IQ Biozoom

THE NEED FOR REGULAR MONITORING OF SELECTED BIOMARKERS IN THE BODY



IQ Biozoom

**84% DIABETICS WANT NON-
INVASIVE MONITORING OF
THE LEVEL OF GLUCOSE**



IQ Biozoom

ATHLETES WHO NEED TO MEASURE THEIR LACTATE LEVEL PREFER NOT TO PRICK



IQ Biozoom

**PEOPLE WITH HORMONAL
DISORDERS AVOID FREQUENT
VISITS TO DIAGNOSTICS AND
CARE POINTS**



IQ Biozoom

MILLIONS OF PEOPLE NEED RELIABLE MONITORING & SELF- TESTING OF SELECTED BIOMARKERS



IQ BIOZOOM DEVELOPS BIOSENSING TECHNOLOGY FOR NON-INVASIVE REAL-TIME DIAGNOSTICS TESTS



New era of self-testing



IQ BIOZOOM WILL ENABLE DEFINING EXACT LEVELS OF BIOMARKERS IN BODY FLUIDS. LIKE PROFESIONAL CLINICAL DIAGNOSTICS LABS.

STATE OF ART:

CURRENT HOME-TESTS GIVE INFO ONLY ABOUT PRESENCE OR ABSENCE OF BIOMARKER. OR INDICATES AN IMPRECISE RANGE.

REVOLUTION:

IQ BIOZOOM PLAN TO DEFINES THE EXACT CONCENTRATION LEVEL OF THE BIOMARKERS IN BODY FLUIDS! WHEREVER YOU ARE. IN REAL-TIME.



Flexibility of out technology

IQ BIOZOOM IS A MATRIX TECHNOLOGY. WE PLAN TO MEASURE DIFFERENT BIOMARKERS IN BODY FLUIDS

BIOMARKER

GLUCOSE (proofed)
LACTATE (proofed)
THYROID HORMONES
CORTISOL
TESTOSTERONE
ESTRADIOL
PROLACTINE
DHEA
INSULINE
TUMOR BIOMARKERS
AND...

BODY FLUID

SALIVA
TEARS
SWEAT
CERVICAL MUCUS
BLOOD
UREA




THE TECHNOLOGY BEHIND THE DEVICE



IQ Biozoom


HOW IT WORKS?




The idea of a product is based on a strip test and a pen-like device



Bring the strip in contact with saliva



The measurement result appears in the display. The device sends the result via Bluetooth to the app in real-time.




You may analyze the results and compare historic biomarker levels, as well as correlations between different biomarkers measured.

ONE DEVICE, MANY KINDS



With one device, you can accurately measure the biomarker you need: e.g. various steroid hormones, glucose, lactate.

Affordable, accurate and simple



- **No cleanroom needed:** room temperature chemical processes
- **Simple and affordable** – no expensive elements in device. As an assumption - inexpensive ways of manufacturing.
- **High throughput technology:** easy to scale by roll-to-roll processes
- **High accuracy:** exact concentration of biomarkers in body fluids. At home! For glucose - one order of magnitude higher than state of the art.

**Our biosensors are
extremely sensitive**

**For glucose - one order of
magnitude higher
sensitivity than state-of-
the-art devices**



Novel transistor-based sensor leverages enzymes

Japanese Journal of Applied Physics **58**, 090603 (2019)




<https://doi.org/10.7567/1347-4065/ab1a65>

STAP ARTICLE

Metal oxide semiconductor thin-films and related devices



IGZO MESFET with enzyme-modified Schottky gate electrode for glucose sensing

Jakub Kaczmarek^{*} , Joanna Jankowska-Śliwińska , and Michał A. Borysiewicz 

Institute of Electron Technology, Al. Lotników 32/46, 02-668, Warsaw, Poland

^{*}E-mail: kaczmarek@ite.waw.pl


Received February 21, 2019; revised March 26, 2019; accepted April 17, 2019; published online May 13, 2019

We describe the development of a glucose sensor through the immobilization of an enzyme (glucose oxidase) into the gate of an In–Ga–Zn–O thin film transistor in a MESFET configuration with Ru–Si–O acting as a Schottky gate electrode. A change in the gate potential, due to a different glucose concentration in the buffer solution causes a change in the width of the depletion region, hence modulating the current in the channel layer. The glucose sensing mechanism of the presented MESFET structure is discussed using energy band diagrams. The sensitivity of the fabricated IGZO MESFET biosensor evaluated from the slope of the linear ranges: from 0 to 2 mmol l⁻¹ and from 2 to 10 mmol l⁻¹, which cover blood, salivary, sudoriferous and lachrymal glucose concentration in humans, equal: 2.23 μA mmol⁻¹ l⁻¹ and 0.41 μA mmol⁻¹ l⁻¹, respectively.

© 2019 The Japan Society of Applied Physics



Established partnerships



**OUR TECHNOLOGICAL
READINESS LEVEL IS TRL 5**


EPO PATENT APPLIED




IQ Biozoom

Our path and present status

Biosensors created in 2019




2019: PROOF-OF-CONCEPT (in laboratory): detecting glucose from saliva.



March, 2023: we are finishing the work on a first demonstrator. Repeating glucose detection. Proofing lactate detection.

2023: Measuring other biomarkers – why possible? The answer is: the electrochemistry



IQ Biozoom

Working on the "heart" of a device - our innovative biosensor based on the proprietary thin-film transistor design, 2023

**WE ARE GOING TO EXPAND
THE PORTFOLIO OF
BIOMARKERS WE CAN
MEASURE**



IQ Biozoom

Types of competitors



At-home colorimetric tests provide information about presence or absence only, or indicate an imprecise range.

ADVANTAGES OF IQBZ

IQBZ determines the exact concentration level of the biomarker in the analyte. Like in a lab, but... at home.



Home tests based on samples that are sent to the lab. The results are obtained over time, remotely, via a mobile app.

ADVANTAGES OF IQBZ

IQBZ gives you the exact result and its interpretation in REAL-TIME, wherever you are and whenever you need it.



Optoelectronic, non-invasive solutions for glucose monitoring are expensive and not very accurate

ADVANTAGES OF IQBZ

Devices based on IQBZ technology don't contain any expensive components. They are much more affordable to manufacture. And more accurate in defining biomarker levels.



Semi-invasive solutions for glucose monitoring require regular replacement and are not good for babies

ADVANTAGES OF IQBZ

No age restrictions. Good even for newborns. One device is able to measure different biomarkers (more than one) Analysis of results, trends and correlations between different biomarkers available



MARKET ADVANTAGES

- ② very high sensitivity and accuracy of measurements
- ② results with exact level of biomarker, in real-time
- ② technological stability
- ② affordability
- ② analysing retrospectively
- ② analysing correlations between biomarkers



THE TEAM



IQ Biozoom

TEAM



Dorota Dardzińska
CEO, co-founder



Paweł Prystawko
Phd
physicist



Tomasz Piętka
*strategy & Business
Development,
advisor*



Jakub Kaczmarcki
Phd
CTO, co-founder



Robert Jachymek
physicist



Magdalena Czarnowska
office manager



Katarzyna Kaczmarcka
Phd
*Medical Affairs,
co-founder*



Krzysztof Gibasiewicz
Phd
physicist



Mateusz Pawelec
*Business
Development, advisor*



Awards

MIT Enterprise Forum



Grand Prize finalist, MIT Bootcamp participant and acceleration programme

Hello Tomorrow Deep Tech Pioneers



Selected as Hello Tomorrow Deep Tech Pioneers 2022: one of the most promising startups worldwide, recognised as „being leaders unlocking the power of deep tech to solve the world's toughest challenges”.

Startup Summer Camp PARP



Grand Prix for The Best Startup of Startup Summer Camp 4 by PARP. TOP50 of the „Start Platforms” acceleration program and grant beneficiary of the Polish Agency for Enterprise Development





**Together with IQ BIOZOOM,
you can deliver better
diagnose and non-invasive
health monitoring to
millions of people**



*This is a visualisation of
hypothetical
products based on IQBZ
technology
in a pharmacy*